Variables predictivas de respuesta a la eritropoyetina recombinante humana en pacientes con anemia y cáncer. / [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer]
Medicina (B.Aires)
; 62(1): 41-7, 2002.
Article
em Es
| BINACIS
| ID: bin-39257
Biblioteca responsável:
AR2.1
ABSTRACT
The use of human recombinant erythropoietin (rHuEpo) has been approved by the Food and Drug Administration (FDA) in patients with anemia and cancer. Although good results have been obtained, it is too expensive to permit its use massively. For the purpose of evaluating the therapeutic effect of rHuEpo, including toxicity, predictive response variables and quality of life parameters, a prospective trial was carried out in patients with anemia and cancer. Hematimetric parameters, ferritin, Epo, cytokines, transfusions and quality of life were registered. A total of 36 patients were treated in the protocol (34 were evaluable) 16 men and 20 women, with a medium age 56.4 years; 27 patients were treated with chemotherapy (16 with cisplatinum); 15 patients presented medullar infiltration. In 73.5
Buscar no Google
Coleções:
06-national
/
AR
Base de dados:
BINACIS
Tipo de estudo:
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Aspecto:
Patient_preference
Idioma:
Es
Revista:
Medicina (B.Aires)
Ano de publicação:
2002
Tipo de documento:
Article
País de publicação:
Argentina